- Home
- UFCS vs EYPT Comparison
UFCS vs EYPT Comparison
Compare UFCS & EYPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | UFCS | EYPT |
|---|---|---|
| Founded | 1946 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Laboratory Analytical Instruments |
| Sector | Finance | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 419.9M |
| IPO Year | 1995 | 2005 |
Fundamental Metrics
Financial Performance| Metric | UFCS | EYPT |
|---|---|---|
| Price | $54.30 | $3.99 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | ★ $40.50 | $31.80 |
| AVG Volume (30 Days) | 113.9K | ★ 3.9M |
| Earning Date | 05-05-2026 | 05-06-2026 |
| Dividend Yield | ★ 2.01% | N/A |
| EPS Growth | ★ 87.45 | N/A |
| EPS | ★ 2.45 | N/A |
| Revenue | ★ $1,386,412,000.00 | $7,539,000.00 |
| Revenue This Year | $11.80 | N/A |
| Revenue Next Year | $8.77 | $3,115.57 |
| P/E Ratio | $22.13 | ★ N/A |
| Revenue Growth | ★ 10.62 | N/A |
| 52 Week Low | $29.75 | $3.95 |
| 52 Week High | $56.74 | $19.11 |
Technical Indicators
Market Signals| Indicator | UFCS | EYPT |
|---|---|---|
| Relative Strength Index (RSI) | 50.55 | 25.99 |
| Support Level | $52.21 | N/A |
| Resistance Level | $55.12 | $18.99 |
| Average True Range (ATR) | 1.38 | 0.31 |
| MACD | -0.09 | 0.18 |
| Stochastic Oscillator | 41.44 | 4.71 |
Price Performance
Historical ComparisonAbout UFCS United Fire Group Inc.
United Fire Group Inc is engaged in the business of writing property and casualty insurance and selling annuities through a network of independent agencies. The company's only operating segment is property and casualty insurance, which includes commercial lines insurance, personal lines insurance, and assumed reinsurance. The primary source of revenue is premium and investment income.
About EYPT EyePoint Pharmaceuticals Inc.
EyePoint Inc focuses is a clinical-stage biopharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained-release product candidate for retinal diseases, with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.